The parties to the Cook IVC filter lawsuits are now in the process of selecting cases that will go into a discovery pool and from this pool, four cases will be chosen for bellwether trials.
These early trials are conducted to help the parties determine how juries will react to the evidence and to facilitate settlement negotiations.
The Cook IVC filter multidistrict litigation (MDL) was established in October 2014 in the Southern District of Indiana.
The lawsuits consolidated into the MDL make similar allegations, including:
IVC filters are medical devices placed between the proximal vessels of the lower extremities and the right side of the heart to help prevent pulmonary embolism by catching blood clots and preventing them from traveling to the lungs.
Over the past 30 years, the use of the IVC filter has steadily increased.
While around 2,000 filters were implanted in patients in the U.S. in 1979, by 1990, over 120,000 IVC filters had been placed, and at the end of the decade, nearly 50,000 IVC filters were being implanted each year.
IVC filters have been linked to life-threatening complications including migration, fraction and perforation, leading to embolism, organ damage and death.
Manufacturers of these devices are facing a growing number of over injuries caused by the implants.
Since 2005, the U.S. Food and Drug Administration (FDA) has received more than 900 reports of adverse events connected to IVC filters.
Common complications associated with IVC filters left in the body for long periods of time include:
According to the FDA, the majority of IVC filters are not retrieved, and their benefits continue to make them a frequent choice for doctors and patients, despite the risk of increased fracture, embolism, and IVC wall penetration.
A new study conducted by Yale School of Medicine researchers shows that the utilization rates of inferior vena cava (IVC) filters vary widely across different regions of the U.S., and is being used in nearly one in six patients, although the best use of the technology remains uncertain.
The Yale team studied over 550,000 Medicare fee-for-service beneficiaries age 65 or older who had been hospitalized for pulmonary embolism between 1999 and 2010.
Researchers found a frequent and increased use of IVC filters in patients with pulmonary embolism over time, even as death from pulmonary embolism decreased during the same period, regardless of whether IVC filters were used or not.
They noted that the 30-day death rate in patients both with and without IVC filters decreased during that time period, raising questions about the best use of this controversial technology.
Of the 556,658 persons studied, more than 15 percent had received an IVC filter.
Head researcher Dr. Behnood Bikdeli commented that IVC filters might be indicated for a select group of patients, but not for such a widespread use, given that the procedure is often costly and not without complications.
We really need good comparative effectiveness studies to determine which patients may benefit from IVC filters, he said.
Experienced Attorney & Legal SaaS CEO
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
Camp Lejeune’s water contamination issue spanned several decades starting in the 1950s. Exposure to these chemicals has been linked to various serious health issues, including cancer, organ diseases, and death.
Research is increasingly suggesting a link between the use of Tylenol during pregnancy and the development of neurodevelopmental disorders, such as autism and ADHD, in infants.
Legal action is being taken against manufacturers of Aqueous Film-Forming Foam (AFFF), a chemical used in fighting fires. The plaintiffs allege that exposure to the foam caused health issues such as cancer, organ damage, and birth and fertility issues.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
Weis Market Inc., a Mid-Atlantic food retailer based in Sunbury, Pennsylvania, has recalled its 48-ounce containers of Weis Quality Brownie Moose Tracks Ice Cream because the product may contain traces of egg, an allergen not declared on the ingredient statement label, according to the FDA.
Marlex Pharmaceuticals, Inc., of New Castle, Delaware, has announced a voluntary, consumer-level recall of one lot of Digoxin Tablets USP, 0125mg, as well as one lot of Digoxin Tablets USP, 0.25mg, because the labels of both products have been mixed up, according to the FDA.